N4 Pharma PLC (N4P) - Total Liabilities
Based on the latest financial reports, N4 Pharma PLC (N4P) has total liabilities worth GBX78.37K GBX (≈ $9.53 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore N4 Pharma PLC (N4P) long-term investment share to see how much of total assets are deployed in long-term investments.
N4 Pharma PLC - Total Liabilities Trend (1985–2024)
This chart illustrates how N4 Pharma PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see N4 Pharma PLC assets under control.
N4 Pharma PLC Competitors by Total Liabilities
The table below lists competitors of N4 Pharma PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jereissati Participações S.A.
SA:IGTI11
|
Brazil | R$4.79 Billion |
|
URU Metals Ltd
LSE:URU
|
UK | GBX3.93 Million |
|
Surgical Innovations Group plc
LSE:SUN
|
UK | GBX4.00 Million |
|
Ahlers AG
F:AAH
|
Germany | €105.97 Million |
|
Bangkok Bank Public Company Limited
F:BKKF
|
Germany | €4.03 Trillion |
|
Coro Energy PLC
LSE:CORO
|
UK | GBX2.59 Million |
Liability Composition Analysis (1985–2024)
This chart breaks down N4 Pharma PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See N4 Pharma PLC net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 23.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how N4 Pharma PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for N4 Pharma PLC (1985–2024)
The table below shows the annual total liabilities of N4 Pharma PLC from 1985 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX124.37K ≈ $15.13 |
+52.18% |
| 2023-12-31 | GBX81.73K ≈ $9.94 |
+4.93% |
| 2022-12-31 | GBX77.89K ≈ $9.48 |
-63.39% |
| 2021-12-31 | GBX212.73K ≈ $25.88 |
+25.81% |
| 2020-12-31 | GBX169.08K ≈ $20.57 |
+117.66% |
| 2019-12-31 | GBX77.68K ≈ $9.45 |
-59.14% |
| 2018-12-31 | GBX190.12K ≈ $23.13 |
+6.08% |
| 2017-12-31 | GBX179.22K ≈ $21.81 |
+132.75% |
| 2016-12-31 | GBX77.00K ≈ $9.37 |
+352.94% |
| 2015-12-31 | GBX17.00K ≈ $2.07 |
-97.89% |
| 2014-12-31 | GBX807.00K ≈ $98.19 |
-10.53% |
| 2013-12-31 | GBX902.00K ≈ $109.75 |
-27.43% |
| 2012-12-31 | GBX1.24 Million ≈ $151.24 |
-15.21% |
| 2011-12-31 | GBX1.47 Million ≈ $178.37 |
+41.51% |
| 2010-12-31 | GBX1.04 Million ≈ $126.05 |
-10.69% |
| 2009-12-31 | GBX1.16 Million ≈ $141.14 |
+109.39% |
| 2008-12-31 | GBX554.00K ≈ $67.41 |
+4.53% |
| 2007-12-31 | GBX530.00K ≈ $64.49 |
+4.13% |
| 2006-12-31 | GBX509.00K ≈ $61.93 |
-86.84% |
| 2005-12-31 | GBX3.87 Million ≈ $470.75 |
-4.89% |
| 2004-12-31 | GBX4.07 Million ≈ $494.96 |
-13.72% |
| 2003-12-31 | GBX4.71 Million ≈ $573.68 |
-2.82% |
| 2002-12-31 | GBX4.85 Million ≈ $590.35 |
-6.84% |
| 2001-12-31 | GBX5.21 Million ≈ $633.66 |
-35.17% |
| 2000-12-31 | GBX8.03 Million ≈ $977.38 |
-8.04% |
| 1999-12-31 | GBX8.73 Million ≈ $1.06K |
-13.52% |
| 1998-12-31 | GBX10.10 Million ≈ $1.23K |
-61.40% |
| 1997-12-31 | GBX26.17 Million ≈ $3.18K |
+11.12% |
| 1996-12-31 | GBX23.55 Million ≈ $2.87K |
-6.58% |
| 1995-12-31 | GBX25.21 Million ≈ $3.07K |
+33.58% |
| 1994-12-31 | GBX18.88 Million ≈ $2.30K |
+55.53% |
| 1993-12-31 | GBX12.14 Million ≈ $1.48K |
-33.39% |
| 1992-12-31 | GBX18.22 Million ≈ $2.22K |
-9.15% |
| 1991-12-31 | GBX20.05 Million ≈ $2.44K |
+223.44% |
| 1990-12-31 | GBX6.20 Million ≈ $754.36 |
-13.95% |
| 1989-12-31 | GBX7.21 Million ≈ $876.64 |
+0.63% |
| 1988-12-31 | GBX7.16 Million ≈ $871.16 |
+17.11% |
| 1987-12-31 | GBX6.11 Million ≈ $743.90 |
+30.17% |
| 1986-12-31 | GBX4.70 Million ≈ $571.49 |
-15.96% |
| 1985-12-31 | GBX5.59 Million ≈ $680.02 |
-- |
About N4 Pharma PLC
N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequen… Read more